FDOPA in Movement Disorders and Neuro-Oncology

Maria Rosana Ponisio; Pooya Iranpour; Tammie L.S. Benzinger

doi:10.1007/978-3-030-82367-2_13

FDOPA in Movement Disorders and Neuro-Oncology

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

The amino acid PET tracer L3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (FDOPA), a radiolabeled analog of L-DOPA, is indicated for the molecular imaging of metabolic abnormalities of presynaptic dopamine transporters and L-type amino acid transporters. In clinical neurology, FDOPA-PET assesses the brain’s dopaminergic function for diagnosing Parkinson’s disease (PD) and differentiation between essential tremor and parkinsonian syndromes. In neuro-oncology, FDOPA-PET uptake measures the rate of L-type amino acid transport activity, given that malignant brain tumors are linked to increased protein synthesis and amino acid transport, resulting in higher uptake than normal tissue. FDOPA-PET is increasingly being used to complement MRI in diagnosing and managing patients with brain tumors, especially gliomas.

Original language	English
Title of host publication	Hybrid PET/MR Neuroimaging
Subtitle of host publication	A Comprehensive Approach
Publisher	Springer International Publishing
Pages	121-135
Number of pages	15
ISBN (Electronic)	9783030823672
ISBN (Print)	9783030823665
DOIs	https://doi.org/10.1007/978-3-030-82367-2_13
State	Published - Jan 1 2021

Keywords

Dopaminergic imaging
FDOPA
FDOPA-PET/MRI
Gliomas
Neuro-oncology imaging
Parkinson’s disease

Access to Document

10.1007/978-3-030-82367-2_13

Cite this

@inbook{2bf0957a7d584da09fd1afe7a4162a3f,

title = "FDOPA in Movement Disorders and Neuro-Oncology",

abstract = "The amino acid PET tracer L3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (FDOPA), a radiolabeled analog of L-DOPA, is indicated for the molecular imaging of metabolic abnormalities of presynaptic dopamine transporters and L-type amino acid transporters. In clinical neurology, FDOPA-PET assesses the brain{\textquoteright}s dopaminergic function for diagnosing Parkinson{\textquoteright}s disease (PD) and differentiation between essential tremor and parkinsonian syndromes. In neuro-oncology, FDOPA-PET uptake measures the rate of L-type amino acid transport activity, given that malignant brain tumors are linked to increased protein synthesis and amino acid transport, resulting in higher uptake than normal tissue. FDOPA-PET is increasingly being used to complement MRI in diagnosing and managing patients with brain tumors, especially gliomas.",

keywords = "Dopaminergic imaging, FDOPA, FDOPA-PET/MRI, Gliomas, Neuro-oncology imaging, Parkinson{\textquoteright}s disease",

author = "Ponisio, \{Maria Rosana\} and Pooya Iranpour and Benzinger, \{Tammie L.S.\}",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.",

year = "2021",

month = jan,

day = "1",

doi = "10.1007/978-3-030-82367-2\_13",

language = "English",

isbn = "9783030823665",

pages = "121--135",

booktitle = "Hybrid PET/MR Neuroimaging",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - FDOPA in Movement Disorders and Neuro-Oncology

AU - Ponisio, Maria Rosana

AU - Iranpour, Pooya

AU - Benzinger, Tammie L.S.

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - The amino acid PET tracer L3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (FDOPA), a radiolabeled analog of L-DOPA, is indicated for the molecular imaging of metabolic abnormalities of presynaptic dopamine transporters and L-type amino acid transporters. In clinical neurology, FDOPA-PET assesses the brain’s dopaminergic function for diagnosing Parkinson’s disease (PD) and differentiation between essential tremor and parkinsonian syndromes. In neuro-oncology, FDOPA-PET uptake measures the rate of L-type amino acid transport activity, given that malignant brain tumors are linked to increased protein synthesis and amino acid transport, resulting in higher uptake than normal tissue. FDOPA-PET is increasingly being used to complement MRI in diagnosing and managing patients with brain tumors, especially gliomas.

AB - The amino acid PET tracer L3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (FDOPA), a radiolabeled analog of L-DOPA, is indicated for the molecular imaging of metabolic abnormalities of presynaptic dopamine transporters and L-type amino acid transporters. In clinical neurology, FDOPA-PET assesses the brain’s dopaminergic function for diagnosing Parkinson’s disease (PD) and differentiation between essential tremor and parkinsonian syndromes. In neuro-oncology, FDOPA-PET uptake measures the rate of L-type amino acid transport activity, given that malignant brain tumors are linked to increased protein synthesis and amino acid transport, resulting in higher uptake than normal tissue. FDOPA-PET is increasingly being used to complement MRI in diagnosing and managing patients with brain tumors, especially gliomas.

KW - Dopaminergic imaging

KW - FDOPA

KW - FDOPA-PET/MRI

KW - Gliomas

KW - Neuro-oncology imaging

KW - Parkinson’s disease

UR - https://www.scopus.com/pages/publications/85159445601

U2 - 10.1007/978-3-030-82367-2_13

DO - 10.1007/978-3-030-82367-2_13

M3 - Chapter

AN - SCOPUS:85159445601

SN - 9783030823665

SP - 121

EP - 135

BT - Hybrid PET/MR Neuroimaging

PB - Springer International Publishing

ER -

FDOPA in Movement Disorders and Neuro-Oncology

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this